Entrada Therapeutics Inc TRDA

$5.25 +0.56 (11.94%)

Valuation

Market cap
182,615,000
Revenue TTM
$25,420,000
Net income TTM
$-143,750,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-565.50%
Debt to equity
0.00

Trading

Volume
582,100
Avg volume
385,456
Day's range
$4.64 – $5.29
Shares out
38,937,000
Stochastic %K
96%
Beta
-0.19
Analysts
Strong Buy
Price target
$18.75

Price

Company profile

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neur...

Show more

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
857 520 9158
Website
https://www.entradatx.com
Address
One Design Center Place, Suite 17- 500, Boston, United States

Latest news

Stocktwits

Merlintrader Nov 11, 5:01 AM
$TRDA Entrada (TRDA): Q3 net loss $39.7M, runway into Q4 2027 Free weekly catalyst newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13 Not investment advice.
0 replies
Merlintrader Nov 9, 8:44 PM
$TRDA Entrada Therapeutics Reports Third Quarter 2026 Financial Results (Nov 5) • Entrada Therapeutics reported financial results for the quarter ended September 30, 2026. • Cash, cash equivalents and marketable securities were $193.0 million, compared to $295.7 million at December 31, 2025, and are expected to fund operations into the fourth quarter of 2027. • Net loss was $39.7 million, compared to $44.1 million a year earlier. Full hub (catalysts, filings & latest news): https://www.merlintrader.com/entrada-therapeutics-trda-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=st-hub-giro&utm_content=trda Free weekly catalyst newsletter — no free trials, no logins, FREE is FREE: https://merlintrader.beehiiv.com/subscribe?utm_source=stocktwits&utm_medium=social&utm_campaign=st-hub-giro&utm_content=trda Not investment advice.
0 replies
Merlintrader Nov 5, 4:52 PM
$TRDA : Entrada Therapeutics Q3 2026 (reported Nov 5): Cash, equivalents and marketable securities $193.0M at Sept 30; Q3 net loss $39.7M; management runway extended into Q4 2027; ELEVATE-44-201 cohort 1 open-label data expected by year-end 2026; Q3 10-Q discloses substantial doubt about going concern within 12 months. Questions worth checking: When are the next Entrada TRDA clinical data readouts? How much cash does Entrada Therapeutics have, and how long is it funded? Are Entrada’s Duchenne medicines FDA approved? Answers, primary sources and downloadable PDF report in our hub: https://www.merlintrader.com/entrada-therapeutics-trda-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=trda_hubpdf_nov26 Not investment advice.
0 replies
d_risk Nov 5, 12:32 PM
$TRDA - Entrada Therapeutics Inc - 10Q - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +371.9% above peer average (56,099 vs 11,889 across 655 peers). Entrada added an explicit warning of substantial doubt about its ability to continue as a going concern. It says additional financing is needed, may be unavailable on acceptable terms, and failure to raise funds could force delays, reductions or discontinuation of development programs or operations. #Biotechnology #FinancialRisk #CapitalRaisingChallenges #CompetitivePressure #PricingPolicy 🟢 Added 🟠 Removed https://d-risk.ai/TRDA/10-Q/2026-11-05
0 replies
Merlintrader Nov 1, 8:44 PM
$TRDA closed the week at $4.53 (+2.8% w/w), below the 50-day SMA ($6.05) and below the 200-day ($8.77). RSI14 40.8. 20-day range $4.11-$5.75. TRDA Stock Hub: Entrada Therapeutics News, Duchenne Programs and Delivery https://www.merlintrader.com/entrada-therapeutics-trda-stock-hub/
0 replies
Rounderssss4 Oct 16, 2:16 PM
$TRDA someone is loading quietly here
0 replies
mds22 Oct 14, 8:03 PM
$TRDA Awesome job by management here - give yourselves a raise. New 52 week low today.
0 replies
NotHopeJustFacts Oct 14, 3:34 PM
$TRDA another biotech failure, GAME OVER
0 replies